标题：黄云生
简介
广东医学院教授，美国北卡大学药物化学专业博士（PhD）。2010至今研究方向：合成利用生物信息设计全新药物；新药合成设计与筛选；药物分子模型计算。主要研究领域：以磷酸甘油脂为载体的靶向抗肿瘤药物研究、Sigma-2受体靶向抗肿瘤药物研究、以Hsp90为靶向的抗病毒药物研究、有机合成肽类、核苷类、甾体类等小分子；发表SCI论文30余篇，获发明专利3项。
学历
美国北卡州立大学工商硕士（MBA）
美国北卡大学药化专业博士（PhD）
北京大学有机化学硕士（MS）
江西大学（现南昌大学）化学学士（BS）
工作经历
1、2010-现在 广东医学院药学院教授，主要研究领域包括：
以磷酸甘油脂为载体的靶向抗肿瘤药物研究
Sigma-2受体靶向抗肿瘤药物研究
以Hsp90为靶向的抗病毒药物研究
诺美孕酮及其衍生物的研究
以偕二磷酸为亲骨性的靶向抗骨质疏松药物研究
2、2007-2009 苏州强达化学医药有限公司（美国公司），副总经理，技术总监
管理一支由近40人组成的研发和中试团队
生物活性分子设计与合成
医药中间体的合成
医药中间体生产工艺的改进
暨南大学生物医药基地的顾问特聘客座教授，指导863合成和衍生物的设计
3、2005-2007 美国Pharmagra公司高级研究员，项目主管
负责抗癌药物分子设计与合成
负责杂环化合物合成研究
负责小分子靶向药物合成开发研究
4、2002-2005 美国Kucera制药公司高级研究员，团队主管
抗艾滋病药物合成
抗肿瘤药物合成
5、1999-2002 美国Anasazi 生物医药研究公司合伙人和项目主要负责人
乳腺癌诊断剂sigma-1、2受体开发
抗乳腺癌药物研究开发
公司的项目和有关专利03年被Mallinckrodt公司收购。
6、1997-1999美国Wake Forest大学医学院副教授
癌症诊断剂sigma-1、2受体设计与合成
7、1995-1996美国Wake Forest大学医学院博士后研究
Sigma-2受体与多巴胺D3受体合成、分子模型设计
8、1989-1990 汕头驼滨化学药业总公司药物研究所，合成一室主任
负责子宫颈成熟药物“优利生”的合成，该项目已获得国家二类新药。
负责“莱普生 ”抗生素的合成工艺的改造，优化。
9、1984-1986江西大学助教
有机化学的教学和实验指导工作
特长
有机合成
肽类、核苷类、甾体类等小分子合成
利用生物信息设计全新药物
新药合成设计与筛选
药物分子模型计算
发表论文
Liu J.Q., Huang Y.S., Zhao Y.Y.,Jia Z.B., Molecular Tectonics of Entangled Metal−Organic Frameworks Based on Different Conformational Carboxylates Mixed with a Flexible N,N′-Type Ligand, Cryst Growth & Des 2011，11, 596-574
Huang, Y., Zhang, W., Zhang, X., Wang, J., Manufacturing synthesis of 5-hydroxy-2-methyl-1H-indole. Res Chem Intermed 2010，36，975–983
Huang, Y., Zhang, W., Zhang, P., Liu, X., Industrial production of tert-butyl-4-oxoazepane-1-carboxylate. Ind Eng Chem Res 2010, 49(23), 12164–12167
Mach R.H., Gage H.D., Buchheimer N., Huang Y., Kuhner R., Wu L., Morton T.E., Ehrenkaufer R.L.. [18F]4’-Fluorobenzyl-4-(2-fluorophenyl)acetamide ([18F]FBFPA): A Potential Fluorine-18 Labeled PET Radiotracer for Imaging Sigma-1 Receptors in the CNS, Synapse, 2005，58，267-274
Mach R.H., Huang Y., Freeman R.A., Wu L., Vangveravong S., Luedtke R.R. Conformationally-flexible benzamide analogs as dopamine D3 and Sigma-2 receptor ligands. Bioorg. Med. Chem. Lett 2004; 14: 195-202.
Mach R.H., Vangveravong S., Huang Y., Yang B., Blair J.B., Wu L. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3a-yl phenylcarbamate analogs as Sigma-2 receptor ligands. Med Chem Res 2003,11,380-398.
Mach RH, Huang Y, Freeman RA, Wu L, and Luedtke RR Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. Bioorg. Med. Chem. 2003, 11, 225-233.
Huang Y, Hammond PS, Wu L, and Mach RH, Synthesis and structure-activity relationships of N- (1-benzylpiperidin-4-yl)aryllacetamide analogues as potent Sigma-1 receptor ligands. J. Med. Chem. 2001, 44 (25), 4404 – 4415.
Huang Y, Luedtke RR, Freeman RA, Wu, L, and Mach RH, Synthesis and Structure-Activity Relationship of naphtnamides as dopamine D3 receptor ligands. J. Med. Chem. 2001, 44(11), 1815-1826.
Huang Y, Luedtke RR, Freeman RA, Wu L, and Mach RH, Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors. Bioorg. Med. Chem. 2001, 9, 3113-3122.
Mach RH, Huang Y, Buchheimer N, Kuhner R, Wu L, Morton TE, Wang, LM, Ehrenkaufer RL,Wallen CA, Wheeler KT, [18F]N-4’-fluorobenzyl-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [18F]FDG and [125I]IUDR. Nucl. Med. Biol. 2001, 28, 451-458.
Luedtke RR, Freeman RA, Boundy VA, Martin MW, Huang Y, and Mach RH, Characterization of 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse, 2000, 38, 438-449.
Mach R.H., Hammond P.S., Huang Y., Yang B., Xu Y., Cheney J.T., Freeman R. and Luedtke R.R. Structure-activity relationship studies of N-(9-benzyl)-9-azabicyclo[3.3.1]nonan-3ß-yl benzamide analogues for dopamine D2 and D3 receptors. Med. Chem. Res. 1999, 9(6), 355-373.
Huang Y, Hammond PS, Whirrett BR, Ross JK, Wu L, Childers SR, and Mach RH, Synthesis and structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective Sigma-1 ligands. J. Med. Chem. 1998, 41, 2361-2370.
Huang Y and Hall IH, Antineoplastic and cytotoxic activity of beta-alkylamino-(para-substituted)propiophenone and beta-alkylamino-(6-methyl)naphthone derivatives in murine and human tissue culture cells. Pharmazie 1998, 53, 117-123.
Huang Y and Hall IH, Hypolipidemic effects of alpha, beta, and gama-alkylaminophenone analogues in rodents. Eur. J. Med. Chem. 1996, 31, 281-290.
Huang Y and Hall IH, Synthesis and pharmacological studies of 3-amino-2-methyl-1-phenyl- propiophenones as hypolipidemic agents in rodents. Arch. Pharm. Pharm. Med. Chem. 1996, 329, 329-338.
Huang Y and Hall IH, Hypolipidemic activity of 3-amino-1-(2,3,4-mononitro-,mono-, or dihalo- phenyl)propan-1-ones in rodents. Arch. Pharm. Pharm. Med. Chem. 1996, 329, 339-346.
Huang Y and Hall IH, Synthesis and hypolipidemic evaluation of ?beta-alkylaminopropiophenone and beta-alkylaminopropio-2’-naphthone derivatives in rodents. Pharmazie 1996, 51, 199-206.
Huang Y and Hall IH, Anti-inflammatory activity of alpha-, beta-, and gama-alkylaminoketones in CF1 mice. Res. Comm. Pharm. & Toxi. 1996, 1, 17-37.
Huang Y and Hall IH, Antineoplastic activities of alpha-, beta-, and gama-alkylaminopropiophenone derivatives in mice and in murine and human tissue culture cells. Anticancer Res. 1996, 16, 597-604.
Huang Y and Hall IH, Antineoplastic activities of 2,3,4-chlorosubstituted beta-alkylamino-propiophenone derivatives in CF1 mice and in murine and human tumor cells. Anti-Cancer Drugs 1996, 7, 613-620.
Butner L, Huang Y, Tse E, and Hall IH, Anti-inflammatory activity of 2,3-dihydrophthalazine-1,4-diones in CF1 mice. Int. J. Tiss. Reac. 1996, XVIII, 47-55.
Butner L, Huang Y, Tse E, and Hall IH, Anti-inflammatory and analgesic activities of 3-imino-1- oxoisoindolines in CF1 mice. Biomed. & Pharmacother. 1996, 50, 290-296.
Tse E, Butner L, Huang Y, and Hall IH, The anti-inflammatory activity of N-substituted indazolones in mice. Arch. Pharm. Pharm. Med. Chem. 1996, 329, 35-40.
Huang Y and Hall IH, Antineoplastic activities of alpha-methyl-beta-alkylaminopropiophenone derivatives in tissue culture cells. Anticancer Res. 1996, 16, 3589-3595.
Ye Y, Huang Y, Wang Z, Chen S, and Tian Y, Synthesis of new amino acid and peptide derivatives of estradiol and their binding affinities for the estrogen receptor. Steroids 1993, 58 (1), 35-39.
He M, Ye Y, He X, Huang Y, Lin X, and Yu Z, Mass spectrometric study of novel estrone derivatives of amino acids and peptides. Org. Mass Spectr. 1992, 27, 636-638.
Chen S; Huang Y; and Ye Y, 13C-NMR study of amino acid, peptide derivatives of estrogenic steroids. Chinese J. Magnetic Resonance 1991, 8 (2), 153-158.
Huang Y and Ye Y, Synthesis of new estrone derivatives of amino acids and peptides. Chinese Chem. Lett. 1991, 2 (2), 99-101.
Ye Y and Huang Y, Amino acid, peptide steroidal derivatives: A review. Chinese J. Med. Chem. 1991, 1, 41-48.
Huang, Y., Huang, H., Tang, H., A convenient one-pot synthesis of 1-indanones. (submitted)
Huang, Y, Kucera L, Fleming R, Synthesis and Evaluation of Amidoglycerol Phosphocholine Analogues as Anti-HIV Agents. (in preparation)
Huang, Y, Jan Hes, Kucera L, Fleming R, Synthesis of Biological Evaluation of (R)-KPC-2 and (S)-KPC-2 as Anti-HIV Agents. (in preparation)
Huang, Y, Kucera G, Fleming R, Synthesis of 1-Acylamino-2-ethyloxy-3-phosphatidyl- 5’-gemcitabine Diester as Potent Anti-cancer Agents . (in preparation)
申请专利
Robert Mach, Yunsheng Huang, Steven Childers, and Kenneth Wheeler, Sigma-1 Ligands for Determining Carcinoma Proliferative Status. WO 2000/71171 A3
Ronald A. Fleming, Jan V. Hes, Yunsheng Huang, Russ Read, Susan Morris-Natschke, Khalid Ishaq, Louis S. Kucera, Phillip A. Furman, Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses, and Coronaviruses. US20050187192
Louis S. Kucera, Ronald A. Fleming, Jan V. Hes, Yunsheng Huang, Russ H. Read, Phillip A. Furman, Susan L. Morris-Natschke, Khalid S. Ishaq, Methods and Compositions for the Treatment of Respiratory Syncytial Virus. WO 2005/099719 A2